S-1/A: Papa Medical Inc. Files Amended IPO Prospectus, Highlighting Strong Q1 2025 Revenue Growth Amidst Evolving Hemp Vapor Market

Sentiment:

IPO Registration Statement Amendment 27 June 2025 2:31 PM

Papa Medical Inc., an end-to-end Hemp dosing solution provider, filed an amended S-1 registration statement detailing its initial public offering of 1,250,000 Class A common shares at an estimated US$4.00 per share, showcasing significant revenue growth in Q1 2025 but facing substantial regulatory and concentration risks.

Capital raiseThe company is undertaking an initial public offering (IPO) of 1,250,000 shares of Class A common stock.The estimated initial public offering price is US$4.00 per share.The company expects to receive net proceeds of approximately US$4,150,000 from the offering, assuming no exercise of the over-allotment option.The underwriters have an option to purchase up to an additional 187,500 shares of Class A common stock to cover over-allotments.The primary purposes of the offering are to create a public market for shares and obtain additional capital.Proceeds are planned to be used for R&D (30.0% or US$1,245,000), upgrading plant and facilities (30.0% or US$1,245,000), sales and marketing (25.0% or US$1,037,500), and working capital/general corporate purposes (15.0% or US$622,500).

Better than expectedTotal revenues for the three months ended March 31, 2025, increased by 107.3% to US$17.9 million, significantly higher than US$8.6 million in the prior year period.Net income for the three months ended March 31, 2025, increased by 152.5% to US$0.8 million, compared to US$0.3 million in the prior year period.

Summary

Papa Medical Inc. is offering 1,250,000 shares of Class A common stock at an estimated initial public offering price of US$4.00 per share, aiming to raise approximately US$4.15 million in net proceeds.
The company is an end-to-end innovative Hemp dosing solution provider in the US, specializing in R&D, formulation design, e-liquid production, filling, and co-packing services for Hemp cannabinoid E-vapors and consuming E-vapors.
Revenue for the three months ended March 31, 2025, increased by 107.3% to US$17.9 million, up from US$8.6 million in the same period of 2024.
Net income for Q1 2025 surged by 152.5% to US$0.8 million, compared to US$0.3 million in Q1 2024.
For the full year 2024, total revenues grew by 49.0% to US$37.7 million from US$25.3 million in 2023, primarily driven by Hemp cannabinoid E-vapors.
However, net income for the full year 2024 decreased by 43.1% to US$0.9 million from US$1.5 million in 2023, largely due to a faster increase in operating expenses than gross profit.
The company's primary revenue streams are Hemp cannabinoid E-vapors (90.3% of Q1 2025 revenue) and consuming E-vapors (1.2% of Q1 2025 revenue).
Papa Medical plans to use IPO net proceeds for R&D (30.0%), upgrading plant and facilities (30.0%), sales and marketing (25.0%), and working capital (15.0%).
The company operates under a dual-class share structure, with CEO Jian Hua holding 96.57% of current voting power, expected to be 94.87% post-IPO, making it a controlled company under Nasdaq rules.
Significant risks include evolving and inconsistent regulations for Hemp cannabinoid products in the U.S., potential changes to the federal definition of Hemp, and high customer and supplier concentration.
The company utilizes proprietary AiMesh technology for precise dosing and feelmixX technology for aroma blending in its Cannapresso brand products, primarily sold on an ODM basis.

Sentiment

Score: 7

Explanation: The company demonstrates strong recent revenue and net income growth, driven by innovative technology and strategic market positioning in a high-growth industry. However, significant regulatory uncertainties, high customer/supplier concentration, and related-party risks temper the overall positive outlook. The IPO itself is a positive step for capital and market visibility.

Positives

Strong revenue growth in the most recent quarter: Total revenues increased by 107.3% to US$17.9 million for the three months ended March 31, 2025, compared to US$8.6 million for the same period in 2024.
Significant net income increase in Q1 2025: Net income rose by 152.5% to US$0.8 million for the three months ended March 31, 2025, from US$0.3 million in Q1 2024.
Consistent annual revenue growth: Total revenues increased by 49.0% from US$25.3 million in 2023 to US$37.7 million in 2024.
Leading market position and innovative technology: The company is identified as the first end-to-end innovative Hemp dosing solution provider in the US with a medical atomization background and is one of the few engaging in No Heat No Burn (NHNB) technology.
Proprietary technologies: AiMesh technology offers precise metering control and consistent dosing, while feelmixX technology combines CBD oil with E-vapor oil for enhanced user experience.
Diversified product offerings: Beyond Hemp cannabinoid E-vapors, the company also sells consuming E-vapors, medical nebulizers, and online candy, with plans to explore the medical products sector further.
Strategic use of IPO proceeds: Funds are allocated to R&D (30.0%), plant and facility upgrades (30.0%), and sales and marketing (25.0%), indicating a clear growth strategy.
Established production capabilities: The California plant has nine highly automated production lines with a monthly capacity of approximately 2 million finished products and 200 tons of e-liquid.
Strong intellectual property: The company holds 11 patents and 10 trademarks in multiple jurisdictions, including the U.S. and mainland China.

Negatives

Decline in annual net income: Net income decreased by 43.1% from US$1.5 million in 2023 to US$0.9 million in 2024, primarily due to operating expenses growing faster than gross profit.
Gross profit margin compression in Q1 2025: Gross profit margin contracted to 22.3% for Q1 2025 from 25.1% for Q1 2024, attributed to volume-related cost increases, product mix adjustments, and strategic price reductions.
Increased operating expenses: Selling and marketing expenses increased by 72.4% in 2024 and 84.4% in Q1 2025, while general and administrative expenses increased by 171.0% in 2024 and 69.9% in Q1 2025.
Negative cash flow from operations in interim periods: Net cash used in operating activities was US$(2.2) million for Q1 2025 and US$(1.3) million for Q1 2024, indicating that operations are consuming cash despite net income.
High customer concentration: Two customers collectively represented approximately 69.2% of total revenues for Q1 2025 and 56.7% for the full year 2024.
High supplier concentration: Three suppliers accounted for approximately 47.8% of total purchases for Q1 2025, and four suppliers accounted for 79.8% of accounts payable as of March 31, 2025.
Reliance on related parties: Significant transactions and balances with Shenzhen Feellife and Cpresso, LLC, both controlled by the CEO, raise potential conflict of interest concerns.
Uninsured cash balances: As of March 31, 2025, US$1,610,438 of cash and cash equivalents held by financial institutions were uninsured by the FDIC.
Immediate and substantial dilution for new investors: The initial public offering price of US$4.00 per share is substantially higher than the pro forma net tangible book value of US$0.19 per share, resulting in a US$3.81 dilution per share for new investors.

Risks

Evolving and stringent regulations: Existing and new laws, regulations, and policies related to the E-vapors and Hemp cannabinoid vapor industry can materially and adversely affect business operations, including potential prohibitions or increased compliance costs.
Changes in Hemp cannabinoid definitions and enforcement: The U.S. federal government could change the definition of Hemp to prohibit Hemp cannabinoid products generally or synthetic hemp cannabinoid products, such as Delta-8 THC, which could make current products illegal.
FDA and DEA enforcement actions: Products could be classified as unapproved new drugs, leading to cease and desist letters, lawsuits, product withdrawals, recalls, seizures, fines, and criminal prosecutions.
Product liability claims and health risks: Uncertainties regarding long-term health effects of E-vapors, potential links to illnesses (e.g., Vitamin E acetate in illicit products), and misuse of products could lead to significant product liability claims and negative publicity.
Controlled company status: CEO Jian Hua's significant voting power (94.87% post-IPO) means the company is a controlled company, potentially exempting it from certain Nasdaq corporate governance requirements, which may limit protection for minority shareholders.
Dependence on key personnel: The company's success relies on retaining its senior management and R&D team, and competition for skilled employees is intense.
Intellectual property infringement: Risk of third-party infringement of the company's IP or claims against the company for infringing others' IP, leading to costly litigation or licensing fees.
Supply chain issues: Reliance on key suppliers, including related parties, exposes the company to supply disruptions, price volatility, and potential inability to meet demands.
Inventory management: Failure to maintain sufficient inventory or adequately manage it could lead to lost sales, higher expenses, obsolescence, or write-downs.
Misconduct by employees/partners: Illegal, fraudulent, or collusive activities could harm brand reputation and adversely affect business.
Uncertainties in PRC laws and regulations: Although primarily U.S.-based, the presence of executive officers in mainland China and potential future changes in PRC laws could impact the company's ability to offer securities or operate.
Public company costs and scrutiny: Incurring increased legal, accounting, and compliance costs as a public company, along with potential for securities litigation.
Volatility of stock price: The trading price may be volatile due to industry factors, regulatory developments, and the relatively small public offering size leading to a concentrated insider holding.
No assurance of active trading market: A liquid public market for Class A common stock may not develop or be sustained after the offering.
No dividends expected: The company does not anticipate paying dividends in the foreseeable future, meaning investors must rely on stock price appreciation for returns.

Future Outlook

Papa Medical Inc. plans to pursue global expansion, commit to R&D innovation, diversify into the medical products sector, scale up production capacity through upgrades to CANNAPRESSO LAB INC., and build industry leadership as a provider of integrated medical and commercial Hemp vaporization solutions in the United States. The company expects its selling and marketing expenses to continue to increase as it expands its sales force and presence, and anticipates additional expenses from operating as a public company. The company believes its current cash, cash generated from operations, and access to capital markets will be sufficient for working capital needs for at least the next twelve months, but may seek additional equity or debt financing for future investments or if cash requirements exceed current amounts.

Management Comments

"We are the first end-to-end innovative Hemp dosing solution provider in the US that possesses the medical atomization or nebulizing background and sells nebulizer, according to the Frost & Sullivan Report."
"We deeply engage in the key activities in the Hemp cannabinoid a E-vapors industry, from the research and development, formulation design, e-liquid production, e-liquid filling to e-liquid co-packing services."
"We believe our full-cycle operations and leading market position will position us to further capitalize on the growth potential of US Hemp cannabinoid E-vapors market."
"This synergy enables us to improve the efficiency of both formulation designing and production process and cover the limits of each other."
"We believe our Hemp cannabinoid E-vapors are well-positioned for broader applications across different sectors, especially the medical industry healthcare industry."
"Our AiMesh technology can effectively solve this issue leveraging its ability to maintain perfect atomization temperature balance."
"We believe the application of our feelmixX technology effectively improves users vaping experience and at the same time creating new possibilities for the innovation and development of Hemp dosing products."
"We are one of the few end-to-end innovative Hemp dosing solution providers in the US that engage in the revolutionization of healthier nicotine ingestion experience with No Heat No Burn (NHNB), according to the Frost & Sullivan Report."
"Our general preparedness and risk management strategies are designed to address the potential impacts of such broad disruptive events [like COVID-19]."
"We believe that we have not experienced a material adverse impact on our financial conditions [from COVID-19]."
"We believe that we have the ability to evaluate and quickly respond to the market need for E-vapors and develop products for both the Hemp cannabinoid E-vapors and consuming E-vapors markets."
"We believe that our full-cycle operations and leading market position enables us to stand out in the Hemp cannabinoid E-vapors and consuming E-vapors markets."
"We believe that we have implemented systems of quality control that cover the key steps of supply chain management to provide high-quality products to end customers in a consistent manner."
"We believe that we are well-positioned to effectively compete on the factors listed above [diversification of R&D personnel, comprehensive qualifications, diversified product layout, efficient supply chain]."

Industry Context

The E-vapors industry, particularly Hemp cannabinoid E-vapors, is experiencing rapid growth in the U.S., with the Hemp cannabinoid E-liquid market size growing from US$879.9 million in 2020 to US$3,057.6 million in 2024 (36.5% CAGR) and projected to reach US$8,890.5 million by 2029 (22.3% CAGR). The Hemp cannabinoid E-vapor market grew from US$502.8 million in 2020 to US$1,528.8 million in 2024 (32.1% CAGR) and is expected to reach US$3,232.9 million by 2029 (15.0% CAGR). The end-to-end Hemp dosing solution industry in the U.S. surged from US$1,728.4 million in 2020 to US$5,733.0 million in 2024 (35.0% CAGR) and is projected to grow to US$15,154.3 million by 2029 (20.1% CAGR). Key market drivers include broadening applications beyond recreation (especially into medical), regulatory clarity post-2018 Farm Bill, strategic integration enhancing consolidation, and diverse product innovations like terpene incorporation and No Heat No Burn (NHNB) technology. Entry barriers are high due to technology, supply chain complexities, stringent qualifications (e.g., California's Industrial Hemp Inhalables Authorization), and established brand loyalty. The nebulizer market in the U.S. also shows robust growth, from US$1.7 billion in 2020 to US$2.6 billion in 2024 (12.1% CAGR), driven by respiratory ailments and technological advancements, with a trend towards civilian use and stricter dosage control.

Comparison to Industry Standards

Papa Medical Inc. claims to be the 'first end-to-end innovative Hemp dosing solution provider in the US that possesses the medical atomization or nebulizing background and sells nebulizer,' suggesting a unique market position compared to traditional vaping corporations and Hemp dosing product brand operators.
The company is identified as one of the 'few end-to-end innovative Hemp dosing solution providers in the US that engage in the revolutionization of healthier nicotine ingestion experience with No Heat No Burn (NHNB),' indicating a competitive edge in advanced, health-conscious vaping technology.
The company's 'AiMesh technology' for precise metering control and 'feelmixX technology' for aroma blending are presented as leading innovations, potentially setting a higher standard for customized and therapeutic vaping experiences compared to generic e-vapor products.
While the industry is fragmented with over 400 participants, Papa Medical positions itself among the less than 50 end-to-end solution providers, implying a more integrated and potentially efficient business model than competitors focused solely on manufacturing or branding.
The company's full-cycle operations, from R&D to co-packing, are stated to offer 'superior cost control' and 'quicker market response times' compared to traditional vaping corporations, aligning with industry trends towards vertical integration for efficiency and quality.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Independent Director and Chair of the Audit Committee	N/A	Joel Adalberto Gallo	Upon SEC's declaration of effectiveness of S-1 registration statement	Appointment in preparation for public listing
Independent Director and Chair of the Nominations Committee	N/A	Douglas Bruce Noyes	Upon SEC's declaration of effectiveness of S-1 registration statement	Appointment in preparation for public listing
Independent Director	N/A	Peter Shihkai Su	Upon SEC's declaration of effectiveness of S-1 registration statement	Appointment in preparation for public listing
Independent Director and Chair of the Compensation Committee	N/A	Dr. James Jiayuan Tong	Upon SEC's declaration of effectiveness of S-1 registration statement	Appointment in preparation for public listing
Chief Financial Officer	N/A (Ms. Yao served as CFO of PAPA Health Inc. since Nov 2022)	Hua Yao	March 2024	Appointment to Papa Medical Inc. (parent company)
Deputy Chief Financial Officer	N/A (Mr. Ye served as financial manager since Dec 2022)	Weilin Ye	May 2024	Appointment to Papa Medical Inc. (parent company)
Chief Operating Officer and Human Resource Manager	N/A (Mr. Lin served as HR Manager since Aug 2023)	Johnathan Tsiho Lin	June 2024	Appointment to Papa Medical Inc. (parent company)

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	The board of directors will consist of six directors upon the SEC's declaration of effectiveness of the registration statement, including four independent directors.	Upon SEC's declaration of effectiveness of S-1 registration statement	Enhances corporate oversight and aligns with public company standards, though the company will be a 'controlled company' under Nasdaq rules.
Committee Establishment	Intends to establish an audit committee, a compensation committee, and a nominations committee under the board of directors.	Prior to completion of this offering	Improves corporate governance structure, providing specialized oversight for financial reporting, executive compensation, and director nominations.
Audit Committee Composition	Audit committee will consist of Joel Adalberto Gallo (Chair), Douglas Bruce Noyes, and James Jiayuan Tong, all satisfying Nasdaq and SEC independence requirements. Joel Adalberto Gallo and James Jiayuan Tong qualify as audit committee financial experts.	Prior to completion of this offering	Ensures robust financial oversight and compliance with regulatory standards for public companies.
Compensation Committee Composition	Compensation committee will consist of Joel Adalberto Gallo, Douglas Bruce Noyes, and James Jiayuan Tong (Chair), all satisfying Nasdaq independence requirements.	Prior to completion of this offering	Provides independent oversight of executive and director compensation, promoting fair and performance-aligned remuneration.
Nominations Committee Composition	Nominations committee will consist of Joel Adalberto Gallo, Douglas Bruce Noyes (Chair), and James Jiayuan Tong, all satisfying Nasdaq independence requirements.	Prior to completion of this offering	Ensures a structured and independent process for identifying and recommending director nominees, contributing to board effectiveness.
Controlled Company Status	Mr. Jian Hua, CEO and director, holds 96.57% of current voting power (expected 94.87% post-IPO), making the company a 'controlled company' under Nasdaq rules. This allows exemptions from certain corporate governance requirements (e.g., majority independent board, independent determination of CEO compensation, independent director nominations).	Upon completion of this offering	May limit the protection afforded to minority shareholders compared to companies fully subject to Nasdaq corporate governance requirements, as Mr. Hua retains significant control over corporate matters.
Indemnification Agreements	The company expects to enter into indemnification agreements with directors and executive officers, agreeing to indemnify them against certain liabilities and expenses.	Expected upon effectiveness of S-1 registration statement	Provides protection to directors and officers, which is essential for attracting and retaining qualified personnel, but SEC policy views such indemnification for Securities Act liabilities as unenforceable.
Dual-Class Share Structure	The company has Class A common stock (one vote per share) and Class B common stock (five votes per share). Mr. Jian Hua holds all Class B shares, ensuring considerable influence over corporate matters.	September 23, 2024 (recapitalization)	Concentrates voting power with the CEO, limiting the ability of Class A shareholders to influence corporate decisions and potentially deterring change-of-control transactions.

Legal Proceedings

As of the date of the prospectus, the company is not a party to any material legal or administrative proceedings.
The company is subject to legal proceedings and regulatory actions in the ordinary course of business, including intellectual property infringement, contract breaches, and labor claims, but does not anticipate a material adverse effect from current matters.
There is a risk of product liability legal claims due to adverse events related to E-vapors, and potential lawsuits from investors if FDA/DEA take enforcement actions or for other product-related reasons.

Related Party Transactions

The company has significant transactions and balances with Shenzhen Feellife and Shenzhen LFS Nebulizer Medical Co., Ltd. (Shenzhen LFS), both directly controlled by CEO Mr. Jian Hua.
Purchases from Shenzhen Feellife amounted to US$1.3 million for Q1 2025, US$1.5 million for Q1 2024, US$4.2 million for FY 2024, and US$2.4 million for FY 2023.
Service expenses paid to Shenzhen Feellife were US$673,237 for Q1 2025, US$422,936 for Q1 2024, US$2.2 million for FY 2024, and US$1.6 million for FY 2023.
The company leases a workshop from Cpresso, LLC, also controlled by Mr. Hua, with rental expenses of US$113,250 for Q1 2025, US$24,000 for Q1 2024, and US$96,000 for both FY 2024 and FY 2023.
As of March 31, 2025, amounts due to Shenzhen Feellife were US$4.3 million, and US$4.8 million as of December 31, 2024, including transferred net balances from twelve other related parties for centralized management and settlement.
The prices paid to Shenzhen Feellife are stated to be in line with market rates, but lease rates paid to Cpresso, LLC were more favorable than market rates until January 1, 2025, when they are expected to adjust.
The company has not considered other potential suppliers for similar services or leased properties, citing risk in relying on third-party suppliers unfamiliar with their products/services.

Stakeholder Impact

**Shareholders (New Investors)**: Will experience immediate and substantial dilution (US$3.81 per share) due to the IPO price being significantly higher than the net tangible book value. Their ability to influence corporate matters will be limited due to the dual-class share structure and the CEO's controlling voting power.
**Shareholders (Existing)**: Will see an immediate increase in net tangible book value (US$0.19 per share) and retain significant control due to the dual-class structure.
**Employees**: The company plans to expand its sales force and R&D personnel, indicating potential job growth. However, competition for highly skilled employees is intense, and the loss of key personnel could adversely affect operations.
**Customers**: Benefit from diversified product offerings, innovative technologies (AiMesh, feelmixX, NHNB), and a commitment to quality control. However, high customer concentration means the loss of major customers could significantly impact the company.
**Suppliers**: The company relies on a concentrated group of suppliers, including related parties. Any interruption from key suppliers could adversely affect the company's ability to produce and deliver products.
**Regulatory Authorities**: The company operates in a highly regulated and evolving industry (Hemp/E-vapors) and faces ongoing scrutiny from agencies like the FDA, DEA, and FTC, with potential for new restrictions, enforcement actions, and legal challenges.
**Creditors**: The company believes its current cash and future operations will meet liquidity needs, but potential future capital raises (equity or debt) could impact debt-to-equity ratios and financial leverage.

Next Steps

Apply to have Class A common stock listed on the Nasdaq Capital Market under the symbol PAPA.
Complete the initial public offering contingent upon final approval of Nasdaq listing.
Utilize net proceeds for R&D, plant/facility upgrades, sales/marketing, and working capital.
Continue global expansion efforts to enter new regional markets.
Further commit to research, development, and innovation, including new series of E-vapors like 'iPrefer'.
Explore the medical products sector for diversification and performance boost.
Enhance production capacity and diversify product offerings through comprehensive upgrade of CANNAPRESSO LAB INC.
Position the company as the leading provider of integrated medical and commercial Hemp vaporization solutions in the United States.
Monitor and comply with evolving U.S. federal and state regulations regarding Hemp and E-vapors, including potential changes to the 2018 Farm Bill and FDA/DEA enforcement priorities.
Establish audit, compensation, and nominations committees under the board of directors prior to the completion of the offering.
Independent directors will assume their roles upon the SEC's declaration of effectiveness of the registration statement.

Key Dates

Date	Description
January 31, 2018	PAPA Health Inc. (formerly Cannapresso Health Inc.) incorporated in California.
January 30, 2020	WHO announced a global health emergency due to COVID-19.
March 2020	WHO classified COVID-19 as a pandemic.
December 2020	FTC initiated its first law enforcement administrative action against six companies selling CBD products.
January 1, 2021	Lease agreement with Cpresso, LLC became effective.
October 21, 2021	USPS issued a rule prohibiting mailing of e-cigarettes and other vaping devices, including Hemp-derived cannabinoid vapor products.
January 1, 2022	Company adopted ASU No. 2016-02, Leases (Topic 842).
January 1, 2022	Business process outsourcing service agreement with Shenzhen Feellife became effective.
May 4, 2022	FDA sent warning letters to five companies selling Delta-8 products.
May 2023	WHO declared COVID-19 an established and ongoing health issue, no longer a public health emergency.
September 23, 2023	Provisions of the 2018 Farm Bill governing Hemp expired.
November 2023	Launched iPrefer 20 and AIR INS U1 products.
November 13, 2023	PAPA Health entered into a three-year warehouse lease agreement with The Mugica Descendants Trust.
January 11, 2024	Papa Medical Inc. incorporated in Delaware.
February 13, 2024	Cannapresso LAB Inc. established in California.
March 2024	Launched iPrefer 30 product.
March 6, 2024	PAPA Health entered into a five-year warehouse lease agreement with Monte Street Properties LLC.
April 1, 2024	Debit Waiver Agreement between the Company and Shenzhen LFS became effective, centralizing related party balances.
April 15, 2024	Company acquired 100% equity interest of PAPA Health Inc. from Shenzhen LFS Nebulizer Medical Co., Ltd.
May 25, 2024	DEUS LAB INC. and QIK.INC established in California.
September 2024	Launched iPrefer 40, iPrefer 43, and AIR INS L1 products.
September 23, 2024	Company effectuated a recapitalization, designating Class A and Class B common stock.
November 2024	Mr. Jian Hua began serving as Chairman of the Board.
February 10, 2025	AirICU Inc. incorporated in California, focused on medical nebulizer R&D, production, and sales.
March 15, 2025	Latest continuing resolution signed, extending the 2018 Farm Bill through September 30, 2025.
June 5, 2025	FY2025 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill passed out of House Agriculture Appropriations Subcommittee.
June 10, 2025	U.S. House Appropriations Committee released its fiscal year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill.
June 11, 2025	Full House Appropriations Committee postponed a final vote on the FY2025 Agriculture Appropriations bill.
June 27, 2025	Date of the S-1/A filing and the audit report.
September 30, 2025	Current expiration date of the 2018 Farm Bill governing Hemp.

Keywords

Hemp cannabinoid E-vapors, E-vapors, Nebulizer, ODM, AiMesh technology, feelmixX technology, No Heat No Burn (NHNB), Cannapresso, IPO, SEC S-1/A, Controlled Company, Delta-8 THC, CBD, Vaping industry, Medical devices, Consumer goods

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.